A Portable Reverse Transcription Recombinase Polymerase Amplification Assay for Rapid Detection of Foot-and-Mouth Disease Virus

Ahmed Abd El Wahed1,2, Ayman El-Deeb3, Mohamed El-Tholoth2, Hanaa Abd El Kader4, Abeer Ahmed5, Sayed Hassan4, Bernd Hoffmann6, Bernd Haas6, Mohamed A. Shalaby3, Frank T. Hufert1, Manfred Weidmann1

1 Department of Virology, University Medical Center, Goettingen, Germany, 2 Virology Department, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt, 3 Virology Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt, 4 Animal Health Research Institute, Giza, Egypt, 5 Animal Health Research Institute, Falyum, Egypt, 6 Institute of Diagnostic Virology, Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany

Abstract

Foot-and-mouth disease (FMD) is a trans-boundary viral disease of livestock, which causes huge economic losses and constitutes a serious infectious threat for livestock farming worldwide. Early diagnosis of FMD helps to diminish its impact by adequate outbreak management. In this study, we describe the development of a real-time reverse transcription recombinase polymerase amplification (RT-RPA) assay for the detection of FMD virus (FMDV). The FMDV RT-RPA design targeted the 3D gene of FMDV and a 260 nt molecular RNA standard was used for assay validation. The RT-RPA assay was fast (4–10 minutes) and the analytical sensitivity was determined at 1436 RNA molecules detected by probit regression analysis. The FMDV RT-RPA assay detected RNA prepared from all seven FMDV serotypes but did not detect classical swine fever virus or swine vesicular disease virus. The FMDV RT-RPA assay was used in the field during the recent FMD outbreak in Egypt. In clinical samples, reverse transcription polymerase chain reaction (RT-PCR) and RT-RPA showed a diagnostic sensitivity of 100% and 98%, respectively. In conclusion, FMDV RT-RPA was quicker and much easier to handle in the field than real-time RT-PCR. Thus RT-RPA could be easily implemented to perform diagnostics at quarantine stations or farms for rapid spot-of-infection detection.

Introduction

FMD is a contagious trans-boundary disease infecting cloven-hoofed animals and leads to huge economic losses (death of young ruminants, diminishes milk, and meat production) [1]. FMDV is a non-enveloped, positive single-stranded RNA virus belonging to the genus Aphthovirus of the Picornaviridae family [2]. It has seven serotypes (A, O, C, SAT 1-3, and Asia1) that have a distinct geographical distribution (A and O are widely distributed across the world, SAT 1-3 mainly in Africa and Asia 1 in Asia) [3]. Europe and North America are free of FMDV. Nevertheless, to date no country is considered safe [4]. There is always a fear of introducing FMDV into a FMDV-free country or a new serotype into a FMDV-endemic country. For example, serotype O was endemic in Egypt since 1960 [5], and in 2006, type A was introduced and caused a FMD outbreak [6]. Recently, SAT 2 was the primary cause of a FMD epidemic in Egypt which erupted in February 2012 and led to 82362 suspected cases, of which 19655 died [7]. Outbreaks due to SAT 2 were also reported from Libya and the Gaza strip [8,9]. It is assumed that FMDV SAT2 was introduced from sub-Saharan Africa where it is endemic [9].

FMDV is highly contagious due to the ability of the causative agent to gain entry and initiate infection via a variety of sites, the small infective dose, the short incubation period, and the release of FMDV before the onset of clinical signs. In addition, the massive quantities of virus excreted from infected animals, its ability to spread large distances due to airborne dispersal and the survivability of the virus in the environment contribute to its contagiousness [10]. It is therefore absolutely necessary to detect a FMD outbreak as early as possible to initiate the appropriate control measures and prevent further spread among livestock. As other diseases may cause clinical signs resembling FMD, often a laboratory confirmation of suspect cases is indispensable. The classical method, virus isolation takes several days and is only possible in a few specialized laboratories. Lateral flow assays [11] and antigen ELISA have a limited sensitivity and yield positive results only with vesicular material but not with saliva, nasal swabs or serum [4]. Currently, laboratory diagnosis of FMD mostly depends on the detection of viral RNA by reverse transcription polymerase chain reaction (RT-PCR) [12–14]. Samples collected from animals in the field or at quarantine stations are sent to central laboratories for testing, as RT-PCR assays are not suitable for on-site screening. Therefore, portable, accurate, simple, and
rapid tests are needed to detect the virus at the spot-of-infection. Recombinase polymerase amplification (RPA) is an isothermal DNA amplification and detection method [15]. The amplification depends on a specific combination of enzymes and proteins (recombinase, single strand binding protein, and strand displacing DNA polymerase) used at a constant temperature. Real-time detection of RPA amplicons is possible via exo-probes. Development of fluorescence depends on the separation of fluorophore and quencher via Exonuclease III cleaving at an internal abasic site mimic (tetrahydrofuran, THF) of the hybridized exo-probe [16,17]. The fluorescence signal is measured in real-time via a simple point-of-care scanner weighing 1.2 kg including the laptop (ESEQuant Tubescanner device, Qiagen Lake Constance GmbH, Stockach, Germany). This study describes the development of a real-time reverse transcription RPA (RT-RPA) assay for the detection of all FMDV serotypes and its use in the 2012 FMD outbreak in Egypt.

Materials and Methods

Ethics Statement

Twenty-seven samples (Table 1) were derived from two animal trial (#FLI 007/08 and #FLI 002/11) performed at the Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany. The two experiments were licensed by the Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern, Thierfelder Str. 18, 18059 Rostock, Germany with following animal welfare license numbers LALLF M-V/ TSD/7221.3-1.1-017/08 and LALLF 7221.3-2.5-002/11.

VIRUSES

All FMDV reference strains used in this study were provided by the World Reference Laboratory for FMDV, Pirbright, UK. FMDV serotype A vaccine strain (A Argentina 2001) was used to prepare the RNA molecular standard. The following FMDV strains were used for the assay validation: O Manisa, O BFS 1860, O TUR28/2011, O TUR33/2011, A24 Cruzeiro, A22 Iraq 24/64, A TUR 29/2011, A TUR64/2011, A BAR18/2011, C Oberbayern, C Noville, Asial Shamir, Asia TUR49/2011, Asia TUR51/2011, Asia TUR 65/2011, Asia PK 5/2012, SAT1 Zimb22/89, SAT2 Egypt 2/2012, SAT2 Egypt 6/2012, SAT2 Libya 40/2012, and SAT3 Zim4/81. Also Swine vesicular disease virus (SVDV ITL/7/07, SVDV ITL/8/07) had been sent to the Friedrich-Loeffler-Institute by the Pirbright Institute, Pirbright, UK. Classical swine fever virus (CSF) (Koslov genotype 1.1) was provided by the German national reference laboratory for CSF, Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany.

Generation of RNA Standard

The FMDV serotype A RNA was reverse transcribed and amplified using the QIAGEN OneStep RT-PCR kit (Qiagen, Hilden, Germany). The forward primer: 5’-CACCTCCACATGGATTAGGAACGTG-3’, and the reverse primer: 5’-ACATCTGAGGGGATTAGCGGTACG-3’ were used to amplify 260 nt of the highly conserved RNA polymerase (3D) gene of FMDV (7839–8098 nt of Genbank accession number AF536538.1, GQ294636.1, EU400597.1, NC_004004.1, ASY93630.1, DQ404158.1, EF532669.1) and were synthesized by TIB MOLBIOL (Berlin, Germany).

RT-RPA Conditions

The FMDV RT-RPA was performed in the laboratory in a 50 μl volume using the TwistAmp™ exo lyophilized kit (TwistDx, Cambridge, UK) and addition of reverse transcriptase (RT) ‘Transcriptor’ (Roche, Mannheim, Germany). 420 nM RPA primers, 120 nM RPA exo-probe, 10 U RT ‘Transcriptor’ (Roche, Mannheim, Germany), 20 U RibLock RNase inhibitor (Fisher, Schwerte, Germany), 2 μM DTT (Roche), 14 mM Mg acetate, 4x TwistAmp™ rehydration buffer (TwistDx), and 1 μl RNA template were added to the RPA strips containing a dried enzyme pellet as described [16]. Fluorescence detection in the FAM channel (excitation 470 nm and detection 520 nm) was performed in an ESEQuant tubescanner (Qiagen Lake Constance GmbH, Stockach, Germany) at 42°C for 20 minutes. A combined threshold and signal slope analysis confirmed by 2nd derivative analysis offered by the tubescanner software was used for signal interpretation. In the field during the FMD 2012 outbreak in Egypt, the real-time RT-RPA assay was carried out using the TwistAmp™ RT exo (TwistDx, Cambridge, UK) according to the following formula: 420 nM RPA primers, 120 nM RPA exo-probe, 14 mM Mg acetate, 4x TwistAmp™ rehydration buffer (TwistDx), and 5 μl RNA template.

Analytical Sensitivity

The analytical sensitivity of the RT-RPA assay was tested using a dilution range from 10^6 to 10^3 molecules/μl of the FMDV RNA standard in 8 replicates, the threshold time was plotted against molecules detected and a semi-log regression was calculated using Prism software (Graphpad Software Inc., San Diego, California). In addition, a probit regression was performed using the Statistica software (StatSoft, Hamburg, Germany).

Specificity

The specificity of the FMDV RT-RPA assay was determined by testing twenty-one RNA preparations from the seven FMDV serotypes (listed above), and twelve FMDV-PCR-negative samples (saliva, serum, milk) from apparently healthy cows provided by the Animal Health Research Institute, Giza, Egypt. In addition, RNA of classical swine fever and swine vesicular disease viruses was screened for cross reactivity.

Clinical Samples

Twenty-seven samples (Table 1) including vesicular material, saliva, serum, blood, and swabs from FMDV-immunization experiments performed at the Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany were used to test the performance of the RT-RPA assay. The results were compared to real-time RT-PCR results.
Figure 1. FMDV RT-RPA primers and exo-probe sequences aligned with the consensus sequence of 100 FMDV 3D genes downloaded from the Genbank. (Geneious® 6.1.5, Biomatters Limited, New Zealand). Mismatches are indicated in bold and underlined. The consensus sequence represents nt 7847–7961 of FMDV sequence JF749843. NNN are sites of the quencher and fluorophore in following order (BHQ1- dT) (Tetrahydrofuran) (FAM-dT). Y is C & T; R: A & G.

Table 1. Detection of FMDV in experimentally infected animals using real-time RT-PCR and RT-RPA.

| Animal ID | Species | Dpi | Sample type | Detection |
|-----------|---------|-----|-------------|-----------|
| P24       | Pig     | 3   | Serum       | 29.37     |
| P24       | Pig     | 3   | Serum       | 15.02     |
| G50       | Goat    | 3   | Serum       | 31.1      |
| G51       | Goat    | 3   | Serum       | 22.55     |
| S8        | Sheep   | 5   | Blood       | 36.14     |
| S11       | Sheep   | 5   | Nasal swabs | 29.34     |
| WB18  | Wild boar | 2  | Nasal swabs | 30.3      |
| WB18  | Wild boar | 3  | Serum       | 19.79     |
| WB18  | Wild boar | 3  | Serum       | 19.79     |
| WB18  | Wild boar | 4  | Nasal swabs | 26.31     |
| WB18  | Wild boar | 12 | Vesicular material | 23.71 |
| WB19  | Wild boar | 4  | Nasal swabs | 24.48     |
| WB19  | Wild boar | 8  | Saliva      | 28.88     |
| WB19  | Wild boar | 12 | Vesicular material | 19.2  |
| WB20  | Wild boar | 2  | Serum       | 17.81     |
| WB20  | Wild boar | 3  | Serum       | 15.37     |
| WB20  | Wild boar | 3  | Nasal swabs | 27.04     |
| WB20  | Wild boar | 3  | Serum       | 19.43     |
| WB20  | Wild boar | 4  | Nasal swabs | 25.32     |
| WB20  | Wild boar | 12 | Vesicular material | 24.4  |
| WB25  | Wild boar | 12 | Vesicular material | 23.84 |
| P165     | Pig     | 12 | Vesicular material | 18.57 |
| P165     | Pig     | 3  | Saliva      | 27.12     |
| P165     | Pig     | 3  | Serum       | 18.63     |
| P165     | Pig     | 4  | Saliva      | 27.64     |
| P161     | Pig     | 4  | Saliva      | 28.31     |
| P161     | Pig     | 4  | Serum       | 15.73     |

Results

FMDV RT-RPA Assay Sensitivity and Specificity

An RNA standard representing 260 nt of the 3D gene of FMDV was produced via in vitro transcription from a plasmid containing a 3D gene fragment. A dilution range of 10^7-10^1 molecules/μl of the FMDV RNA standard was used to determine the analytical sensitivity of the RT-RPA assay in comparison to a real-time RT-PCR assay. To select a highly sensitive RT-RPA assay, combinations of forward primers (F), reverse primers (R), and exo-probes (P) listed in the Figure S1 in File S1 were tested. The sensitivity of most of the combinations was very low (e.g. 10^5 molecules detected with F14+R19+P1). F04+R20+P2 yielded analytical sensitivity of 10^5 RNA molecules detected (Figure 2) and was used for further assay validation. The time required to perform the assay to the limit of detection was 10 minutes (Figure 3A). Additionally, a probit regression analysis was performed using a data set of eight RT-RPA runs on the molecular RNA standard. The limit of detection in 95% of cases was 1436 RNA (Figure 3B). Interestingly, using an exo-probe designed for the reverse complementary strand (P2, Figure 1 & 2) yielded a better sensitivity than the positive sense exo-probe (P1, Figure S1 in File S1). In an attempt to shorten the exo-probes, P3, P4, synthesized with locked nucleic acid nucleotides (LNA) were tested but showed a very low sensitivity of 10^6 RNA molecules detected (Figure S2 in File S1) and non-specific detection (Figure S3 in File S1).
S2B in File S1), respectively. To confirm sensitivity of the RT-RPA assay, the RNA of twenty-one FMDV strains listed in material and methods part representing all serotypes were screened and all were detected (Figure S3 in File S1). In addition, unspecific amplification or detection was not observed on twelve FMDV-free samples from cows. No cross detections of the RNA of classical swine fever virus and swine vesicular disease virus was observed.

Assay Performance on Clinical Samples

Twenty-seven samples encompassing vesicular materials, saliva, serum, blood, and swabs were collected from animals immunized with FMDV serotype A (A22 Iraq 24/64) and serotype O (Bulgaria 2011). The total RNA extracts of each sample were tested with both real-time RT-PCR and RT-RPA at the Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany. In comparison to RT-PCR, the sensitivity of the RT-RPA assay was 74% (n = 27, Table 1). The real-time RT-PCR cycle threshold values for the false negative samples in RT-RPA ranged from 27.04 – 31.1, and 36.14 (Table 1). Nevertheless, samples showing high cycle threshold values up to 39 in real-time RT-PCR (see below, Table S1 in File S1) indicating a very low molecular load were also scored positive by RT-RPA. The presence of relevant sequence variations was excluded because all FMDV strains were detected by RT-RPA. Therefore, the false negative results might be due to presence of inhibitors of the RT-RPA amplification and/or detection phase.

During the FMD outbreak in Egypt (spring 2012), a mobile RT-RPA unit was deployed. Forty-five samples were screened (Table S1 in File S1). The total RNA extracted from each sample was tested with real-time RT-PCR (PCR-eg) and the RT-RPA assay using the RT exo kit (RPA-Twist) at the Animal Health Research Institute, Giza and the provincial laboratory Faiyum, Egypt. Inactivated RNA extracts were also tested with real-time RT-PCR [13] (PCR-de) and RT-RPA using the exo kits from Twist Dx™ in combination with RT “Transcriptor” (Roche, Mannheim, Germany) (RPA-Roche) at the virology Department, Goettingen, Germany. The sensitivities of PCR-eg, PCR-de, RPA-Twist, and RPA-Roche were 89, 100, 62, and 98% (n = 45), respectively. RT-RPA using RT “Transcriptor” was more sensitive than RT-RPA using the NuV based RT-RPA kit (Twist Dx™). A linear regression analysis of RPA-Roche threshold time and PCR-de cycle threshold was performed. No correlation was found between RT-PCR and RT-RPA values (R squared 0.26, Figure 4) but samples showing high cycle threshold values in real-time RT-PCR (e.g. 33.88 and 39.65, Table S1 in File S1) were also detected by RT-RPA. A linear regression analysis of the cycle threshold values of PCR-eg and PCR-de was calculated and R squared was 0.35 (Figure S4 in File S1).

Discussion

Currently, molecular methods to detect FMDV are mostly used to confirm or rule out FMD in suspected cases. The only method routinely employed is RT-PCR, usually in the form of a real-time assay [13]. However, it is difficult to perform this test outside of a well-equipped laboratory as real-time cyclers and even mobile real-time cyclers are quite heavy, expensive, complex and must be operated by qualified staff. In addition, test run times are usually between 60-90 minutes. RT-PCR is therefore not suitable for routine point-of-care detection of FMDV. However, there clearly
is a need for highly sensitive “pen-side” tests in the control of infectious animal diseases [4]. Laboratories may be overwhelmed by the number of samples in case of a large FMD epidemic. In any case, it will at least take several hours until the official veterinarian receives a laboratory result and thus may have to base his decision to cull a holding on clinical signs in suspected cases. Unless an FMD outbreak happens next to a well-equipped laboratory, only fast and highly sensitive point-of-care detection will make it feasible to cull confirmed FMDV positive animals in the incubation phase, i.e. before they can infect many other susceptible animals. In endemically infected countries, culling usually is not feasible, but highly sensitive point-of-care assays could contribute to FMD control by quickly providing a sound scientific basis for decisions on animal movement restrictions. In addition to confirm suspected clinical cases, it may make sense to check animals for FMDV at border control posts or on livestock markets. It is sometimes suggested to test also for persistent infection, but FMDV excretion by persistently infected animals is intermittent and thus even samples of optimal quality tested in a highly sensitive real-time RT-PCR will miss many carrier animals. Still, in some situations, e.g. if serological assays for antibodies to (infection-induced) non-structural proteins of FMDV can not resolve an unclear situation in a vaccinated population, herd testing by point-of-care assays may help to detect persistent infected animals. RT-RPA is carried out at a constant temperature (42°C) and results are produced in maximum 15 minutes, on a lightweight portable device (ESEQuant tubescanner). In this study an RT-RPA assay for the detection of FMDV was developed.

A FMDV molecular standard based on the 3D gene was used to determine the analytical sensitivity of the RT-RPA assay. Dozens of primers and exo-probes (Figure S1 in File S1) were tested to select an effective combination yielding a high sensitivity. Only the combination F04 (34 nt, GC content 41.1), R20 (22 nt, CG content 47.8) and P2 achieved a high analytical sensitivity (1436 RNA molecules detected, Figure 3B).

There are no clear-cut rules for the design of primers and exo-probe other than the advice mentioned on the Twist Dx website [http://www.twistdx.co.uk]. Primers should be 30–35 nt in length, not contain multiple Gs in the first 5 bp of the 5’-end, and the GC content should be between 40–60%. Interestingly, R20, which yielded the highest RT-RPA sensitivity, is 22 nt in length, has two Gs at the 5’-end (Figure 1) and contains the lowest GC content of all reverse primers used in this study (47.8%, Table S2 in File S1). The RT-RPA primers were analyzed with Visual OMP (DNA software, MI, USA) for secondary structure and to determine the changes in the target secondary structure upon hybridization to primers [19]. All primers formed folded secondary structures (Figure S5 in File S1). In silico hybridization of the primers to the target sequence induced secondary structure changes of the target molecule (Figure S6 in File S1). Thus it appears that the successful combination of primers and exo-probe exerted an influence on the secondary structure of the target, which facilitated the RT-RPA amplification and detection process whereas the unsuccessful primers induced more complicated secondary structures not amenable to the RT-RPA reaction (see Figure S6 B and C in File S1).

According to exo-probe design rules, the exo-probe should be placed into the positive sense strand, and consist of at least 30 nt to the 5’ and 15 nt to the 3’ of the abasic site mimic. In contrast, P2, yielding a RT-RPA sensitivity increased by one log10-step, was designed complementary to the positive sense strand. It has 16 nt 5’ and 32 nt 3’ of the abasic site mimic and carries an inverse arrangement of fluorophore and quencher.
The detection step in RT-RPA depends on the separation between the fluorophore and its quencher via Exonuclease activity which releases the shorter sequence containing the quencher [15]. Then the shorter sequence containing the quencher is released and fluorescence is detected. In the approach recommended by Twist DX, the long 3'-part of the exo-probe and its non-protected 3'-end could influence amplification by acting as a primer in unwanted extension after release of the short 3'-part of the exo-probe. In contrast the short 16 nt 5'-part of P2 is removed leaving the hybridized long 32 nt phosphor group blocked 3'-part of P2, which therefore cannot be extended or otherwise interfere with further amplification. To improve RT-RPA design it might be necessary to consider this feature in exo-probe design in order to reduce interference of the hybridized exo-probe section with amplification. The same principle has been used in the design of real-time PCR, TaqMan probes, which are blocked at their 3'-end to avoid the consumption of reactions component in unfavourable probe extension [20].

The analytical sensitivity of the FMDV RT-RPA assay using F04, R20 and P2 was 1436 RNA molecules as determined by probit analysis of the results of eight assay runs (Figure 3B). The analytical sensitivity of the published real-time RT-PCR was 10 RNA molecules detected [13]. Nevertheless, the diagnostic sensitivity of the RT-RPA for the detection of FMDV during the outbreak in Egypt was 98% (Table S1 in File S1). The lowest titer of FMDV in the saliva of infected cows a few hours before the outbreak in Egypt was 98% (Table S1 in File S1). The lowest sensitivity of the RT-RPA for the detection of FMDV during outbreaks is 10^6 RNA molecules detected [13]. Nevertheless, the diagnostic sensitivity of the RT-RPA for the detection of FMDV during outbreaks is 10^6 [13].

Figure S1, FMDV RT-RPA primers and probe sequences. Nineteen forward primers (F), 4 probes (P), and 20 reverse primers (R) were tested to select combinations yielding the highest analytical RPA sensitivity. NNN are sites of the quencher and fluorophore in following order (BHQ1-dT) (Tetrahydrofuran (FAM-dT)). LNA is probe containing locked nucleic acid (Bold and underlined). RC is the reverse complementary of the original sequence used in the experiment. Figure S2, The FMDV RT-RPA sensitivity with probes containing LNA nucleotide. Fluorescence development over time using a dilution range of 10^-10 molecules/µl of the FMDV RNA standard (Graph generated by ESEquant tubescanner software). A: F04+R20+P3 were used for the amplification and detection steps and the sensitivity was 10^6, 10^5 represented by dot; 10^4, box; 10^3, triangular; 10^2, diamond; 10^1, star; 10^0, vertical-line; 10^0, horizontal-line; negative control, plane line. B: grey line is control negative with F04+R20+P4; black, F04+R20+P4+10^5 of FMDV molecular standard; red, F04+R20+P4+10^5 of FMDV molecular standard; blue, F04+R20+P3+10^5 of FMDV molecular standard.

Supporting Information

**File S1** Figure S1, FMDV RT-RPA primers and probe sequences. Nineteen forward primers (F), 4 probes (P), and 20 reverse primers (R) were tested to select combinations yielding the highest analytical RPA sensitivity. NNN are sites of the quencher and fluorophore in following order (BHQ1-dT) (Tetrahydrofuran (FAM-dT)). LNA is probe containing locked nucleic acid (Bold and underlined). RC is the reverse complementary of the original sequence used in the experiment. Figure S2, The FMDV RT-RPA sensitivity with probes containing LNA nucleotide. Fluorescence development over time using a dilution range of 10^-10 molecules/µl of the FMDV RNA standard (Graph generated by ESEquant tubescanner software). A: F04+R20+P3 were used for the amplification and detection steps and the sensitivity was 10^6, 10^5 represented by dot; 10^4, box; 10^3, triangular; 10^2, diamond; 10^1, star; 10^0, vertical-line; 10^0, horizontal-line; negative control, plane line. B: grey line is control negative with F04+R20+P4; black, F04+R20+P4+10^5 of FMDV molecular standard; red, F04+R20+P4+10^5 of FMDV molecular standard; blue, F04+R20+P3+10^5 of FMDV molecular standard.

Acknowledgments

Authors thanks Andrea Koch (Institute of Virology, Georg-August-University, Goettingen, Germany) and Anja Schulz (Friedrich-Loeffler-Institute, Greifswald-Insel Riems, Germany) for technical help, as well as Dr. Osama Selim, Dr. Soheir Hassan (General organization of Veterinary services, Giza, Egypt), and Prof. Dr. Mohamed Galal Agour (Animal Health Research Institute, Giza, Egypt) for support during the field study in Egypt.

Author Contributions

Conceived and designed the experiments: AAEW MAS FTH MW. Performed the experiments: AAEW AED MET HA AA SH B. Hoffmann B. Haas. Analyzed the data: AAEW B. Hoffmann B. Haas MAS FTH MW. Contributed reagents/materials/analysis tools: AED MET HA AA SH B. Hoffmann B. Haas. Wrote the paper: AAEW MW. Critical revision of the manuscript: AAEW AED MET HA AA SH B. Hoffmann B. Haas MAS FTH MW. FMDV screening during outbreak in Egypt 2012: AED MET HA AA MAS.
References

1. Knowles NJ, Samuel AR (2003) Molecular epidemiology of foot-and-mouth disease virus. Virus research 91: 65–80.
2. Boothroyd JC, Highfield PE, Cross GA, Roslands DJ, Lower PA, et al. (1981) Molecular cloning of foot and mouth disease virus genome and nucleotide sequences in the structural protein genes. Nature 290: 800–802.
3. Rodriguez LL, Gay CG (2011) Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert review of vaccines 10: 377–387.
4. Longam N, Deh R, Sarmah AK, Taya T, Awachat VB, et al. (2011) A Brief Review on Diagnosis of Foot-and-Mouth Disease of Livestock: Conventional to Molecular Tools. Veterinary medicine international 2011: 903768.
5. Ghoneim NH, Abdel-Karim AK, El-Shehawy L, Abdel-Moein KA (2010) Foot and mouth disease in animals in Sharkia governorate - Egypt. Transboundary and emerging diseases 57: 19–21.
6. Knowles NJ, Wadsworth J, Reid SM, Swabey KG, El-Kholy AA, et al. (2007) Foot-and-mouth disease virus serotype A in Egypt. Emerging infectious diseases 13: 1595–1596.
7. FAO (2012) Foot-and-mouth disease caused by serotype SAT2 in Egypt and Libya: A Regional concern for animal health in North Africa and the Middle East. EMPRES WATCH 25.
8. Ahmed HA, Salem SA, Habachi AR, Arafia AA, Aggour MG, et al. (2012) Emergence of foot-and-mouth disease virus SAT 2 in Egypt during 2012. Transbound Emerg Dis 13: 1593–1596.
9. Valdazo-Gonzalez B, Knowles NJ, Hammond J, King DP (2012) Genome sequences of SAT 2 foot-and-mouth disease viruses from Egypt and Palestinian Autonomous Territories (Gaza Strip). J Virol 86: 8901–8902.
10. Sanson RL, Gloster J, Burgin L (2011) Reanalysis of the start of the UK 1967 to 1968 foot-and-mouth disease epidemic to calculate airborne transmission probabilities. Vet Res 169: 336.
11. Ferris NP, Nordergahm A, Hutchings GH, Reid SM, King DP, et al. (2009) Development and laboratory validation of a lateral flow device for the detection of foot-and-mouth disease virus in clinical samples. J Virol Methods 155: 10–17.
12. Callahan JD, Brown F, Osorio FA, Sur JH, Kramer E, et al. (2002) Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus. J Am Vet Med Assoc 220: 1636–1642.
13. Pharo HJ (2002) Foot-and-mouth disease: an assessment of the risks facing New Zealand. N Z Vet J 50: 46–55.
14. Callahan JD, Brown F, Osorio FA, Sur JH, Kramer E, et al. (2002) Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus. J Am Vet Med Assoc 220: 1636–1642.
15. Piepenburg O, Williams CH, Stemple DL, Armes NA (2006) DNA detection using recombination proteins. PLoS biology 4: e204.
16. Euler M, Wang Y, Neutwich O, Piepenburg O, Hufert FT, et al. (2012) Recombinase polymerase amplification assay for rapid detection of Rift Valley fever virus. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
17. Euler M, Wang Y, Otto-P, Tomaso H, Escudero R, et al. (2012) Recombinase Polymerase Amplification Assay for Rapid Detection of Francisella tularensis. Journal of clinical microbiology 50: 2234–2238.
18. Weidmann M, Meyer-König U, Hufert FT (2003) Rapid detection of herpes simplex virus and varicella-zoster virus infections by real-time PCR. J Clin Microbiol 41: 1565–1568.
19. SantaLucia J Jr (2007) Physical principles and visual-OMP software for optimal PCR design. Methods Mol Biol 402: 3–34.
20. Holland PM, Abramson RD, Watson R, Gelfand DH (1991) Detection of RNA viruses. Methods enzymol 198: 621–640.